<DOC>
	<DOCNO>NCT00002804</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , surgery , radiation therapy treat child advance soft tissue sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Surgery , Radiation Therapy Treating Children With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response vincristine/ifosfamide/doxorubicin ( VID ) granulocyte colony-stimulating factor support child newly diagnose , inoperable metastatic non-rhabdomyosarcoma soft tissue sarcoma . II . Estimate 2-year event-free survival rate child treat VID plus radiotherapy and/or surgery . III . Establish bank frozen tumor peripheral blood tissue use molecular study . OUTLINE : The follow acronym use : DOX Doxorubicin , NSC-123127 G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 IFF Ifosfamide , NSC-109724 Mesna Mercaptoethane sulfonate , NSC-113891 VCR Vincristine , NSC-67574 VID VCR/IFF/DOX Induction : 3-Drug Combination Chemotherapy . VID . Local Control : Surgery and/or Radiotherapy plus 3-Drug Combination Chemotherapy . Excision primary tumor pulmonary metastasis ; and/or irradiation primary tumor pulmonary metastasis use x-rays Co60 beam energy least 4 MV ( electron iridium-192 implant allow boost ) ; plus VID . Continuation : 3-Drug Combination Chemotherapy . VID . PROJECTED ACCRUAL : A total 40 patient enter 2.7 year least 7 response first 20 patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven nonrhabdomyosarcoma soft tissue sarcoma ( NRSTS ) Evaluable residual tumor initial biopsy excision require Registration require within 42 day definitive diagnosis Grade II/III , unresectable metastatic disease The following histology exclude : Angiofibroma nasopharynx Mesothelioma Desmoid tumor Peripheral neuroepithelioma Desmoplastic small cell tumor Rhabdomyosarcoma Extraosseous Ewing 's sarcoma Undifferentiated sarcoma Kaposi 's sarcoma Grade 1 NRSTS , include : Angiomatoid malignant fibrous histiocytoma Dermatofibrosarcoma protuberans Myxoid welldifferentiated liposarcoma Welldifferentiated infantile hemangiopericytoma Welldifferentiated malignant peripheral nerve sheath tumor PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine normal age No hydronephrosis Cardiovascular : Shortening fraction great 28 % Other : No HIV infection Not pregnant nursing Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No prior nephrectomy ( surgical correction hydronephrosis allow )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
</DOC>